Back to Results

A Phase 1a/b Dose-Finding Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Wells Messersmith,  MD

Wells Messersmith, MD

Study ID

Protocol Number: 19-1458

More information available at ClinicalTrials.gov: NCT04068896

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers